PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0011860|type 2 diabetes |
| Sentences | 22 |
| PubMedID- 19959755 | It remains to be evaluated whether the extent of ir/igf-ir activation in breast cancer specimen correlates with underlying type 2 diabetes and hyperinsulinemia in breast cancer patients. |
| PubMedID- 25762476 | The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. |
| PubMedID- 24834121 | In a second study, dr fontanella and colleagues investigated the incidence of type 2 diabetes in patients with early breast cancer at the time of diagnosis, as well as its effect on the outcome after neoadjuvant chemotherapy. |
| PubMedID- 20376506 | In particular, several studies clearly indicate an association between type 2 diabetes and the risk of colorectal, pancreatic, and breast cancer. |
| PubMedID- 23401790 | It was concluded that the risk of breast cancer in women with type 2 diabetes is increased by 27%, but decreased to 16% after the adjustment for bmi. |
| PubMedID- 20941806 | Thus, hyperinsulinaemia may be one of the factors in the increased breast cancer risk seen with obesity and type 2 diabetes. |
| PubMedID- 25304261 | Obesity and type 2 diabetes (t2d) are associated with increased breast cancer incidence and mortality, whereas carbohydrate-restricted ketogenic diets ameliorate t2d and suppress breast cancer. |
| PubMedID- 25679392 | Association of type 2 diabetes genetic variants with breast cancer survival among chinese women. |
| PubMedID- 21972408 | Previous epidemiologic research suggests a modestly elevated risk of breast cancer in women with type 2 diabetes (t2d), particularly after menopause (1). |
| PubMedID- 26148588 | Aim: we tend to explore the expression characteristics of proteins in igf/ir axis in breast cancer with type 2 diabetes mellitus (t2dm). |
| PubMedID- 20801951 | Taken together, pharmacological mtor blockade is sufficient to abrogate mammary tumor progression in the setting of hyperinsulinemia, and thus mtor inhibitors may be an attractive therapeutic modality for breast cancer patients with type 2 diabetes. |
| PubMedID- 20490716 | The coexistence of type 2 diabetes with breast cancer may result in poorer cancer-related survival due to a number of mediating factors including an alteration of tumor tissue hormonal sensitivity. |
| PubMedID- 20077000 | In conclusion, type 2 diabetes is associated with poor breast cancer prognosis. |
| PubMedID- 24281091 | The finding implicates a promising role of early administration of insulin-sensitizing therapy in prolonging survival of breast cancer patients with type 2 diabetes mellitus. |
| PubMedID- 22996614 | Conclusion: the risk of breast cancer in women with type 2 diabetes is increased by 27%, a figure that decreased to 16% after adjustment for bmi. |
| PubMedID- 21133604 | Our study aimed to compare the clinicopathologic characteristics of breast cancers in women with and without type 2 diabetes mellitus in china. |
| PubMedID- 24944108 | The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. |
| PubMedID- 26137275 | Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus. |
| PubMedID- 24338167 | Clinicopathologic features of breast cancer patients with type 2 diabetes mellitus in southwest of china. |
| PubMedID- 20181294 | Previous studies suggest a modest increase in risk of breast cancer among women with type 2 diabetes and gestational diabetes [5]. |
| PubMedID- 26537234 | Mammalian target of rapamycin (mtor) is activated by insulin and insulin-mediated breast cancer progression in patients with type 2 diabetes mellitus may be abrogated by inhibition of mtor [5]. |
| PubMedID- 21614572 | Conclusions/interpretation: the risk of breast cancer in women with type 2 diabetes is not increased during the first 5 years of insulin glargine use. |
Page: 1